4//SEC Filing
Scott Randal W. 4
Accession 0000950170-24-069401
CIK 0001743881other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 4:53 PM ET
Size
9.4 KB
Accession
0000950170-24-069401
Insider Transaction Report
Form 4
Scott Randal W
Director
Transactions
- Sale
Common Stock
2024-06-03$28.68/sh−800$22,948→ 5,700 total(indirect: By LLC) - Sale
Common Stock
2024-06-03$29.48/sh−200$5,895→ 5,500 total(indirect: By LLC) - Sale
Common Stock
2024-06-04$31.30/sh−1,500$46,950→ 4,000 total(indirect: By LLC)
Holdings
- 5,000
Common Stock
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
- [F2]Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001337801
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 4:53 PM ET
- Size
- 9.4 KB